Audentes Therapeutics Inc. (BOLD) Climbed To A New High On Study News

Audentes Therapeutics Inc. (BOLD) announced positive interim results from the first dose cohort of its Phase 1/2 clinical trial of AT132 Thursday morning.

from RTT - Before the Bell http://ift.tt/2lWDRUo
via IFTTT